Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
13 mars 2024 16h05 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
Retail Opportunity Investments Corp. Schedules First Quarter Earnings Release and Conference Call
11 mars 2024 09h00 HE
|
Retail Opportunity Investments Corp.
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Retail Opportunity Investments Corp. (NASDAQ: ROIC) will issue financial and operational results for the first quarter ended March 31, 2024, after the...
Arbutus to Participate in Two Upcoming Investor Conferences
08 mars 2024 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a...
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
07 mars 2024 16h01 HE
|
MacroGenics, Inc.
Presentation of preliminary data from TAMARACK Phase 2 study of vobra duo in mCRPC patients expected at ASCO 2024Initiation of Phase 1 study of MGC026, MacroGenics' first topoisomerase I...
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
07 mars 2024 07h00 HE
|
Optinose, Inc.
PDUFA target action date is March 16, 2024, for the Company's sNDA. If approved, the Company is prepared for launch of XHANCE for treatment of patients diagnosed with chronic sinusitis Physicians...
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
06 mars 2024 07h01 HE
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, March 06, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
CytoSorbents to Report Fiscal 2023 Operating and Financial Results
06 mars 2024 07h00 HE
|
CytoSorbents
PRINCETON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
Broadwind Announces Fourth Quarter and Full-Year 2023 Results
05 mars 2024 07h00 HE
|
Broadwind, Inc.
CICERO, Ill., March 05, 2024 (GLOBE NEWSWIRE) -- Broadwind (Nasdaq: BWEN, or the “Company”), a diversified precision manufacturer of specialized components and solutions serving global markets,...
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
29 févr. 2024 16h40 HE
|
Optinose, Inc.
YARDLEY, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
29 févr. 2024 07h30 HE
|
Arbutus Biopharma Corporation
On-track to report key clinical data in 2024 from two on-going Phase 2a clinical trials with imdusiran and the Phase 1a/1b clinical trial with AB-101 Plans to initiate a third Phase 2a clinical...